These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 38263507

  • 21. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.
    Shinozaki S, Osawa H, Hayashi Y, Sakamoto H, Miura Y, Lefor AK, Yamamoto H.
    Kaohsiung J Med Sci; 2017 Dec; 33(12):616-622. PubMed ID: 29132551
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
    Miyamoto M, Manabe N, Haruma K.
    Intern Med; 2010 Dec; 49(15):1469-76. PubMed ID: 20686276
    [Abstract] [Full Text] [Related]

  • 23. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
    Simadibrata DM, Syam AF, Lee YY.
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
    [Abstract] [Full Text] [Related]

  • 24. Different dosages of vonoprazan for gastroesophageal reflux disease: study protocol for a pragmatic, crossover-cluster, randomized controlled trial with patient preference arms.
    Wang D, Zhou D, Liu X, Xu Z, Bai T, Hou X.
    Trials; 2023 Dec 01; 24(1):778. PubMed ID: 38041136
    [Abstract] [Full Text] [Related]

  • 25. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
    Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, Koike T, Hongo M, Chiba T, Kinoshita Y, Acid-Related Symptom Research Group.
    J Gastroenterol; 2011 Nov 01; 46(11):1273-83. PubMed ID: 21861141
    [Abstract] [Full Text] [Related]

  • 26. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
    Abe Y, Koike T, Saito M, Okata T, Nakagawa K, Hatta W, Asanuma K, Uno K, Asano N, Imatani A, Masamune A.
    Digestion; 2021 Nov 01; 102(3):480-488. PubMed ID: 32062650
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
    Takeuchi T, Hongo H, Kimura T, Kojima Y, Harada S, Ota K, Takeuchi N, Noguchi T, Inoue T, Murano M, Higuchi K.
    J Gastroenterol; 2019 Nov 01; 54(11):972-983. PubMed ID: 31037449
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of vonoprazan for 24-week maintenance therapy of patients with healed reflux esophagitis refractory to proton pump inhibitors.
    Mizuno H, Yamada K, Minouchi K, Kamiyamamoto S, Hinoue Y.
    Biomed Rep; 2018 Feb 01; 8(2):148-155. PubMed ID: 29435273
    [Abstract] [Full Text] [Related]

  • 29. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
    Kusano M, Hosaka H, Kawamura O, Kawada A, Kuribayashi S, Shimoyama Y, Yasuoka H, Mizuide M, Tomizawa T, Sagawa T, Sato K, Yamada M.
    J Gastroenterol; 2015 Mar 01; 50(3):298-304. PubMed ID: 24919745
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis.
    Zhuang Q, Chen S, Zhou X, Jia X, Zhang M, Tan N, Chen F, Zhang Z, Hu J, Xiao Y.
    Am J Gastroenterol; 2024 May 01; 119(5):803-813. PubMed ID: 38345252
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Vonoprazan fumarate for the management of acid-related diseases.
    Martinucci I, Blandizzi C, Bodini G, Marabotto E, Savarino V, Marchi S, de Bortoli N, Savarino E.
    Expert Opin Pharmacother; 2017 Aug 01; 18(11):1145-1152. PubMed ID: 28657473
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
    Chandan S, Deliwala S, Mohan BP, Ramai D, Dhindsa B, Bapaye J, Kassab LL, Chandan OC, Facciorusso A, Adler DG.
    Indian J Gastroenterol; 2023 Aug 01; 42(4):475-484. PubMed ID: 37418052
    [Abstract] [Full Text] [Related]

  • 38. Vonoprazan (Voquezna) for nonerosive GERD.
    Med Lett Drugs Ther; 2024 Oct 14; 66(1713):164-166. PubMed ID: 39382430
    [No Abstract] [Full Text] [Related]

  • 39. A systematic review with meta-analysis: Efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis.
    Simadibrata DM, Lesmana E, Pratama MIA, Sugiharta AJ, Winarizal AS, Lee YY, Syam AF.
    JGH Open; 2024 Mar 14; 8(3):e13053. PubMed ID: 38523708
    [Abstract] [Full Text] [Related]

  • 40. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
    Habu Y.
    Intern Med; 2019 Sep 01; 58(17):2427-2433. PubMed ID: 31178490
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.